活血化瘀促进肿瘤血管正常化的机制探讨_West China Medical Journal

Authors：

 铁明慧 ,  张颖

四川大学华西医院中西医结合科（成都，610041）;

Corresponding author：

张颖, Email: 18980602088@189.cn

Keywords：

肿瘤; 活血化瘀; 抗血管治疗; 血管正常化

DOI：

10.7507/1002-0179.20140720

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

血瘀证在肿瘤患者中极为常见，活血化瘀法治疗肿瘤在临床上应用广泛。但活血化瘀药物抗肿瘤的作用机制尚不明确，对肿瘤血管生成的作用是促进或抑制，一直颇有争议。从诱导肿瘤血管正常化出发，探讨活血化瘀药物的作用，阐明活血化瘀药物促进肿瘤血管正常化的机制，以期从根本上阐明活血化瘀药物治疗肿瘤，增加放射治疗、化学疗法药物疗效的新机制，为活血化瘀药物用于肿瘤治疗提供依据，也为探讨更理想有效的中西医结合综合治疗肿瘤方案提供依据。

Citation： 铁明慧, 张颖. 活血化瘀促进肿瘤血管正常化的机制探讨. West China Medical Journal, 2014, 29(12): 2379-2381. doi: 10.7507/1002-0179.20140720 Copy

1.	李兴华, 吕刚, 卜凡儒, 等. 活血化瘀法防治恶性肿瘤研究进展[J]. 中医临床研究, 2012, 4(13):113-115.
2.	王文江, 孙珏. 活血化瘀防治恶性肿瘤侵袭转移研究进展[J]. 江西中医药, 2013, 44(7):69-73.
3.	孟华, 朱妙章, 郭军, 等. 中药当归、川芎、丹参提取液促血管生成作用的实验研究[J]. 中药材, 2006, 29(6):574-576.
4.	杨运高, 华何与, 陈先明, 等. 中药抵当汤对小鼠结肠癌脾移植肝转移模型肿瘤增殖细胞核抗原的影响[J]. 中国老年学杂志, 2013, 33(3):579-581.
5.	吴胤瑛, 李恩孝. VEGF在恶性肿瘤中的研究进展[J]. 现代肿瘤医学, 2005, 13(5):附18-附21.
6.	高连印, 韦艾凌. 活血化瘀药调控肝细胞癌微环境细胞因子影响肿瘤转移复发机制初探[J]. 环球中医药, 2014, 7(2):119-121.
7.	王茵萍, 邹移海, 潘华峰, 等. 活血化瘀防治胃癌的效应与抗新生血管生成的关系[J]. 中国中西医结合消化杂志, 2005, 13(3):187-189.
8.	Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000, 407(6801):249-257.
9.	Mcdonald DM, Choyke PL. Imaging of angiogenesis:from microscope to clinic[J]. Nat Med, 2003, 9(6):713-725.
10.	Zhao J, Salmon H, Samtinoranont M. Effect of heterogenous vasculature on interstitial transport within a solid tumor[J]. Microvasc Res, 2007, 73(3):224-236.
11.	Fukumura D, Jain RK. Tumor microvasculature and microenvironment:targets for anti-angiogenesis and normalization[J]. Microvasc Res, 2007, 74(2-3):72-84.
12.	Huang G, Chen L. Tumor vasculature and microenvironment normalization:a possible mechanism of antiangiogenesis therapy[J]. Cancer Biother Radiopharm, 2008, 23(5):661-667.
13.	Folkman J. Tumor angiogenesis:therapeutic implications[J]. N Engl J Med, 1971, 285(21):1182-1186.
14.	Steeg PS. Angiogenesis inhibitors:motivators of metastasis?[J]. Nat Med, 2003, 9(7):822-823.
15.	Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:role of oxygenation, angiopoietin-1, and matrix metalproteinases[J]. Cancer Cell, 2004, 6(6):553-563.
16.	Wong CS, Sceneay J, House CM, et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy[J]. Cancer Res, 2012, 72(7):1694-1704.
17.	Shen G, Li Y, Du T, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy[J]. Neoplasma, 2012, 59(5):486-493.
18.	El Kaffas A, Giles A, Czarnota GJ. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound[J]. Angiogenesis, 2013, 16(2):443-454.
19.	Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3):220-231.
20.	Ebos JM, Lee CR, Cruz-Munoz WA, et al. Accelerated metastasis after Short-Term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15(3):232-239.
21.	Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer, 2008, 8(8):592-603.
22.	Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab:pooled analysis of randomized phase Ⅲ trials[J]. J Clin Oncol, 2011, 29(1):83-88.
23.	Padera TP, Kuo AH, Hoshida T, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib[J]. Mol Cancer Ther, 2008, 7(8):2272-2279.
24.	Jain RK. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307(576):58-62.
25.	Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases[J]. Nat Rev Drug Discov, 2011, 10(6):417-427.
26.	Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases[J]. Physiol Rev, 2011, 91(3):1071-1121.
27.	Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7):1253-1256.
28.	王秀丽, 周亚兴, 李海燕. 活血化瘀对血管内皮功能的影响[J]. 中国医院用药评价与分析, 2010, 10(10):956-957.
29.	周曾同, 金芝贵, 张水龙, 等. 灯盏细辛对金地鼠颊囊癌血管生成影响的形态特征研究[J]. 临床口腔医学杂志, 2000, 16(3):166-169.
30.	陈绪元, 朱宇熹, 陈晓品, 等. 平消胶囊与放疗同步治疗中晚期鼻咽癌增敏研究[J]. 临床肿瘤学杂志, 2005, 10(2):163-165.
31.	耿长新, 曾昭冲, 王吉耀. 多烯紫杉醇在体内对肝癌的抑制和放射增敏作用[J]. 中华肝脏病杂志, 2005, 13(1):60-61.
32.	乔新梅, 赵金岭. 血府逐瘀汤联合化疗治疗瘀阻肺络证小细胞肺癌40例疗效观察[J]. 新中医, 2013, 4(2):55-56.

1. 李兴华, 吕刚, 卜凡儒, 等. 活血化瘀法防治恶性肿瘤研究进展[J]. 中医临床研究, 2012, 4(13):113-115.
2. 王文江, 孙珏. 活血化瘀防治恶性肿瘤侵袭转移研究进展[J]. 江西中医药, 2013, 44(7):69-73.
3. 孟华, 朱妙章, 郭军, 等. 中药当归、川芎、丹参提取液促血管生成作用的实验研究[J]. 中药材, 2006, 29(6):574-576.
4. 杨运高, 华何与, 陈先明, 等. 中药抵当汤对小鼠结肠癌脾移植肝转移模型肿瘤增殖细胞核抗原的影响[J]. 中国老年学杂志, 2013, 33(3):579-581.
5. 吴胤瑛, 李恩孝. VEGF在恶性肿瘤中的研究进展[J]. 现代肿瘤医学, 2005, 13(5):附18-附21.
6. 高连印, 韦艾凌. 活血化瘀药调控肝细胞癌微环境细胞因子影响肿瘤转移复发机制初探[J]. 环球中医药, 2014, 7(2):119-121.
7. 王茵萍, 邹移海, 潘华峰, 等. 活血化瘀防治胃癌的效应与抗新生血管生成的关系[J]. 中国中西医结合消化杂志, 2005, 13(3):187-189.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000, 407(6801):249-257.
9. Mcdonald DM, Choyke PL. Imaging of angiogenesis:from microscope to clinic[J]. Nat Med, 2003, 9(6):713-725.
10. Zhao J, Salmon H, Samtinoranont M. Effect of heterogenous vasculature on interstitial transport within a solid tumor[J]. Microvasc Res, 2007, 73(3):224-236.
11. Fukumura D, Jain RK. Tumor microvasculature and microenvironment:targets for anti-angiogenesis and normalization[J]. Microvasc Res, 2007, 74(2-3):72-84.
12. Huang G, Chen L. Tumor vasculature and microenvironment normalization:a possible mechanism of antiangiogenesis therapy[J]. Cancer Biother Radiopharm, 2008, 23(5):661-667.
13. Folkman J. Tumor angiogenesis:therapeutic implications[J]. N Engl J Med, 1971, 285(21):1182-1186.
14. Steeg PS. Angiogenesis inhibitors:motivators of metastasis?[J]. Nat Med, 2003, 9(7):822-823.
15. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation:role of oxygenation, angiopoietin-1, and matrix metalproteinases[J]. Cancer Cell, 2004, 6(6):553-563.
16. Wong CS, Sceneay J, House CM, et al. Vascular normalization by loss of Siah2 results in increased chemotherapeutic efficacy[J]. Cancer Res, 2012, 72(7):1694-1704.
17. Shen G, Li Y, Du T, et al. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy[J]. Neoplasma, 2012, 59(5):486-493.
18. El Kaffas A, Giles A, Czarnota GJ. Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound[J]. Angiogenesis, 2013, 16(2):443-454.
19. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3):220-231.
20. Ebos JM, Lee CR, Cruz-Munoz WA, et al. Accelerated metastasis after Short-Term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15(3):232-239.
21. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy[J]. Nat Rev Cancer, 2008, 8(8):592-603.
22. Miles D, Harbeck N, Escudier B, et al. Disease course patterns after discontinuation of bevacizumab:pooled analysis of randomized phase Ⅲ trials[J]. J Clin Oncol, 2011, 29(1):83-88.
23. Padera TP, Kuo AH, Hoshida T, et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib[J]. Mol Cancer Ther, 2008, 7(8):2272-2279.
24. Jain RK. Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307(576):58-62.
25. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases[J]. Nat Rev Drug Discov, 2011, 10(6):417-427.
26. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases[J]. Physiol Rev, 2011, 91(3):1071-1121.
27. Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy[J]. Cancer Sci, 2011, 102(7):1253-1256.
28. 王秀丽, 周亚兴, 李海燕. 活血化瘀对血管内皮功能的影响[J]. 中国医院用药评价与分析, 2010, 10(10):956-957.
29. 周曾同, 金芝贵, 张水龙, 等. 灯盏细辛对金地鼠颊囊癌血管生成影响的形态特征研究[J]. 临床口腔医学杂志, 2000, 16(3):166-169.
30. 陈绪元, 朱宇熹, 陈晓品, 等. 平消胶囊与放疗同步治疗中晚期鼻咽癌增敏研究[J]. 临床肿瘤学杂志, 2005, 10(2):163-165.
31. 耿长新, 曾昭冲, 王吉耀. 多烯紫杉醇在体内对肝癌的抑制和放射增敏作用[J]. 中华肝脏病杂志, 2005, 13(1):60-61.
32. 乔新梅, 赵金岭. 血府逐瘀汤联合化疗治疗瘀阻肺络证小细胞肺癌40例疗效观察[J]. 新中医, 2013, 4(2):55-56.

Previous Article
推进医院非在编职工加入工会工作的探讨
Next Article
CYP2C19基因多态性与个体化治疗的研究进展

West China Medical Journal

活血化瘀促进肿瘤血管正常化的机制探讨

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content